Clinical trial
Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or…
NCT00143065 · Ohio State University Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00143065 |
|---|---|
| Title | Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
| Official title | Feasibility/Phase II Trial of Fludarabine, Rituximab, and Alemtuzumab for Previously Treated B-Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) |
| Lead sponsor | Ohio State University Comprehensive Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Small Lymphocytic, Lymphocytic Leukemia, Chronic |
| Intervention type | Drug |
| Interventions | Fludarabine, Rituximab, Alemtuzumab |
| Enrollment | 8 |
| Start date | Aug 1, 2005 |
| Primary completion | Feb 1, 2007 |
| Completion | Jul 1, 2009 |
| First posted | Sep 2, 2005 |
| Last update posted | Feb 8, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: